Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 10/2012

01-10-2012 | Original Article

Risk Factors for Postoperative Pancreatic Fistulization Subsequent to Enucleation

Authors: Céline Brient, Nicolas Regenet, Laurent Sulpice, Laurent Brunaud, Stéphanie Mucci-Hennekine, Nicolas Carrère, Jenifer Milin, Ahmet Ayav, Bernard Pradere, Antoine Hamy, Laurent Bresler, Bernard Meunier, Eric Mirallié

Published in: Journal of Gastrointestinal Surgery | Issue 10/2012

Login to get access

Abstract

Introduction

Pancreatectomies increase the risk of postoperative pancreatic fistula (POPF) and pancreatic insufficiency. Pancreatic enucleation preserves pancreatic parenchyma, lowers the risk of pancreatic insufficiency, but may induce specific complications (tumor recurrence or pancreatic fistulization). The aim of this study was to determine the risk factors for POPF following a pancreatic enucleation.

Methods

A retrospective analysis was designed based on data from patients who underwent pancreatic enucleation in five university hospitals (1998–2008). The presence of a pancreatic fistula was determined according to the criteria of the International Study Group of Pancreatic Fistula (Bassi et al. Surgery 138:8–13, 2005).

Results

Fifty-two patients (mean age 52 years) were included. Histological analysis revealed 35 endocrine tumors (68.6 %), 6 mucinous and 2 serous cyst adenomas, 2 metastases of renal cancer, and 8 benign tumors. Nineteen patients (36.5 %) suffered postoperative complications including 14 POPF (27 %). Median postoperative hospital stay was 12.9 days; 9.1 days without POPF versus 29 days with POPF (p < 0.05). Size of the tumor, its location, histological differentiation, and use of somatostatin analogs were not predictors for POPF. We defined the cutoff for POPF at a distance of 2 mm from the main pancreatic duct based on 60 % risk (≤2 mm) versus 19 % (>2 mm) of POPF (p < 0.01). With a mean follow-up of 30.8 months, one patient experienced recurrence of the tumor. No patients exhibited a new onset of diabetes or pancreatic insufficiency.

Conclusion

Enucleation for resection of pancreatic tumors located at less than or equal to two 2 mm from the main pancreatic duct is a risk factor for POPF. Enucleation is a safe and effective treatment for benign or borderline pancreatic tumors.
Literature
1.
go back to reference Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition Surgery 2005; 138:8–13.PubMedCrossRef Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition Surgery 2005; 138:8–13.PubMedCrossRef
2.
go back to reference Bassi C, Falconi M, Salvia R, Mascetta G, Molinari E, Pederzoli P. Management of complications after pancreaticoduodenectomy in a high volume centre: results on 150 consecutive patients. Dig Surg 2001; 18:453–457.PubMedCrossRef Bassi C, Falconi M, Salvia R, Mascetta G, Molinari E, Pederzoli P. Management of complications after pancreaticoduodenectomy in a high volume centre: results on 150 consecutive patients. Dig Surg 2001; 18:453–457.PubMedCrossRef
3.
go back to reference Falconi M, Mantovani W, Crippa S, Mascetta G, Salvia R, Pederzoli P. Pancreatic insufficiency after different resections for benign tumours. Br J Surg 2008; 95:85–91.PubMedCrossRef Falconi M, Mantovani W, Crippa S, Mascetta G, Salvia R, Pederzoli P. Pancreatic insufficiency after different resections for benign tumours. Br J Surg 2008; 95:85–91.PubMedCrossRef
4.
go back to reference Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol 2004; 18: 947–955.PubMed Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol 2004; 18: 947–955.PubMed
5.
go back to reference Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P. Enucleation of pancreatic neoplasms. Br J Surg 2007; 94:1254–1259PubMedCrossRef Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P. Enucleation of pancreatic neoplasms. Br J Surg 2007; 94:1254–1259PubMedCrossRef
6.
go back to reference Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, Cai LX. Surgical Management of Patients With Insulinomas: Result of 292 Cases in a Single Institution. J Surg Oncol 2011; 103:169–74PubMedCrossRef Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, Cai LX. Surgical Management of Patients With Insulinomas: Result of 292 Cases in a Single Institution. J Surg Oncol 2011; 103:169–74PubMedCrossRef
7.
go back to reference Michael W. Müller, MD, Helmut Friess, MD, Jörg Kleeff, MD, Ulf Hinz, MSc, Moritz N. Wente, MD, Daniel Paramythiotis, MD, Pascal O. Berberat, MD, Güralp O. Ceyhan, MD, and Markus W. Büchler, MD An Option to Treat Benign Pancreatic Body Lesions. Ann Surg. 2006; 244: 909–920.PubMedCrossRef Michael W. Müller, MD, Helmut Friess, MD, Jörg Kleeff, MD, Ulf Hinz, MSc, Moritz N. Wente, MD, Daniel Paramythiotis, MD, Pascal O. Berberat, MD, Güralp O. Ceyhan, MD, and Markus W. Büchler, MD An Option to Treat Benign Pancreatic Body Lesions. Ann Surg. 2006; 244: 909–920.PubMedCrossRef
8.
go back to reference Sauvanet A., Surgical complications of pancreatectomy. J Chir 2008; 145:103–14.CrossRef Sauvanet A., Surgical complications of pancreatectomy. J Chir 2008; 145:103–14.CrossRef
9.
go back to reference Bassi C. Middle segment pancreatectomy: a useful tool in the management of pancreatic neoplasms? J Gastrointest Surg 2007; 11:726–9.PubMedCrossRef Bassi C. Middle segment pancreatectomy: a useful tool in the management of pancreatic neoplasms? J Gastrointest Surg 2007; 11:726–9.PubMedCrossRef
10.
go back to reference Molinari E, Bassi C, Salvia R, Butturini G, Crippa S, Talamini G, Falconi M, Pederzoli P. Amylase value in drains after pancreatic resection as predictive factor of postoperative pancreatic fistula: results of a prospective study in 137 patients. Ann Surg. 2007; 246:281–7.PubMedCrossRef Molinari E, Bassi C, Salvia R, Butturini G, Crippa S, Talamini G, Falconi M, Pederzoli P. Amylase value in drains after pancreatic resection as predictive factor of postoperative pancreatic fistula: results of a prospective study in 137 patients. Ann Surg. 2007; 246:281–7.PubMedCrossRef
11.
go back to reference Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien–Dindo Classification of Surgical Complications: Five-Year Experience Ann Surg: 2009; 250: 187–196CrossRef Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien–Dindo Classification of Surgical Complications: Five-Year Experience Ann Surg: 2009; 250: 187–196CrossRef
12.
go back to reference Casadei R, Ricci C, Rega D, D’Ambra M, Pezilli R, Tomassetti P, Campana D, Nori F, Minni F. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Pancreas 2010:39:825–8PubMedCrossRef Casadei R, Ricci C, Rega D, D’Ambra M, Pezilli R, Tomassetti P, Campana D, Nori F, Minni F. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Pancreas 2010:39:825–8PubMedCrossRef
13.
go back to reference Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, Weber SM, Wilson SD, Howard TJ, Talamonti MS, Rikkers LF. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg 2009:13:1692–8PubMedCrossRef Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, Weber SM, Wilson SD, Howard TJ, Talamonti MS, Rikkers LF. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg 2009:13:1692–8PubMedCrossRef
14.
go back to reference Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, and al.. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6:17–32.PubMedCrossRef Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, and al.. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6:17–32.PubMedCrossRef
15.
go back to reference Goasguen N, Bourrier A, Ponsot P, Bastien L, Lesurtel M, Prat F, Dousset B, Sauvanet A. Endoscopic management of pancreatic fistula after distal pancreatectomy and enucleation. AmJ Surg. 2009; 197:715–20.CrossRef Goasguen N, Bourrier A, Ponsot P, Bastien L, Lesurtel M, Prat F, Dousset B, Sauvanet A. Endoscopic management of pancreatic fistula after distal pancreatectomy and enucleation. AmJ Surg. 2009; 197:715–20.CrossRef
16.
go back to reference Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomised trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997; 226: 632–641.PubMedCrossRef Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomised trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997; 226: 632–641.PubMedCrossRef
17.
go back to reference Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg. 1995; 221:635–648.PubMedCrossRef Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg. 1995; 221:635–648.PubMedCrossRef
18.
go back to reference Fendrich V, Merz MK, Waldmann J, Langer P, HeverHagen AE, Dietzel K, Bartsch DK. Neuroendocrine pancreatic tumors are risk factors for pancreatic fistula after pancreatic surgery. Dog Surg 2011; 28:263–9.CrossRef Fendrich V, Merz MK, Waldmann J, Langer P, HeverHagen AE, Dietzel K, Bartsch DK. Neuroendocrine pancreatic tumors are risk factors for pancreatic fistula after pancreatic surgery. Dog Surg 2011; 28:263–9.CrossRef
19.
20.
go back to reference Fernández-Cruz L, Blanco L, Cosa R, Rendón H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg. 2008; 32:904–17.PubMedCrossRef Fernández-Cruz L, Blanco L, Cosa R, Rendón H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg. 2008; 32:904–17.PubMedCrossRef
21.
go back to reference Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005; 137:597–605PubMedCrossRef Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005; 137:597–605PubMedCrossRef
22.
go back to reference Isla A, Arbuckle JD, Kekis PB, Lim A, Jackson JE, Todd JF, Lynn J. Laparoscopic management of insulinomas. Br J Surg. 2009; 96:185–90.PubMedCrossRef Isla A, Arbuckle JD, Kekis PB, Lim A, Jackson JE, Todd JF, Lynn J. Laparoscopic management of insulinomas. Br J Surg. 2009; 96:185–90.PubMedCrossRef
23.
go back to reference Ramos-De la Medina A, Sarr MG. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. J Hepatobiliary Pancreat Surg. 2006; 13:190–3.PubMedCrossRef Ramos-De la Medina A, Sarr MG. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. J Hepatobiliary Pancreat Surg. 2006; 13:190–3.PubMedCrossRef
24.
go back to reference Connor S, Alexakis N, Garden OJ, Leandros E, Bramis J, Wigmore SJ. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg. 2005; 92:1059–67.PubMedCrossRef Connor S, Alexakis N, Garden OJ, Leandros E, Bramis J, Wigmore SJ. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg. 2005; 92:1059–67.PubMedCrossRef
25.
go back to reference Zeng Q, Zhang Q, Han S, Yu Z, Zheng M, Zhou M, Bai J, Jin R. Efficacity of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas. 2008; 36:18–25.PubMedCrossRef Zeng Q, Zhang Q, Han S, Yu Z, Zheng M, Zhou M, Bai J, Jin R. Efficacity of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas. 2008; 36:18–25.PubMedCrossRef
Metadata
Title
Risk Factors for Postoperative Pancreatic Fistulization Subsequent to Enucleation
Authors
Céline Brient
Nicolas Regenet
Laurent Sulpice
Laurent Brunaud
Stéphanie Mucci-Hennekine
Nicolas Carrère
Jenifer Milin
Ahmet Ayav
Bernard Pradere
Antoine Hamy
Laurent Bresler
Bernard Meunier
Eric Mirallié
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 10/2012
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-012-1971-x

Other articles of this Issue 10/2012

Journal of Gastrointestinal Surgery 10/2012 Go to the issue